Effectiveness of Three Times of Starting Antibiotic Prophylaxis in Patients With Asymptomatic Bacteriuria.
Effectiveness of Three Different Times of Starting Antibiotic Prophylaxis in Patients With Asymptomatic Bacteriuria Scheduled for Urological Surgery. A Randomized Multicentric Clinical Trial
1 other identifier
interventional
456
1 country
1
Brief Summary
Asymptomatic bacteriuria (AB) is the isolation of a bacterium in a sample of urine appropriately collected from a person who does not have signs or symptoms of urinary infection. It is common in diabetic women, in pregnant women, in men over 60 years and in patients with spinal cord injury. There is clinical evidence that AB should be treated in patients who will be operated on with urologic surgery because of the risk of presenting infectious complications; however, the timing of initiating antibiotic therapy has not been established, even in some studies the prophylaxis has been considered from one to seven days prior to the procedure, without determining the differences in the outcome for each one of the interventions and causing an undue and risky use of antibiotics. A randomized, parallel-design, single-masked clinical trial will be performed to compare and analysis the bloodstream infections, surgical site infections, readmissions and hospital stay in three intervention groups, 1) those receiving antibiotics during the previous 5 days to the procedure; 2) 3 days prior to the procedure; and 3) those who receive only a single dose of antibiotic on the day of the procedure. The main expected result is to identify the timing of initiation of antibiotic prophylaxis in urological procedures in patients with asymptomatic bacteriuria, with the purpose of diminishing the bloodstream and of the surgical site infections. If it is scientifically demonstrated that those patients who receive a single dose of antibiotic on the same day of the procedure, have the same safety and effectiveness compared to the other two groups, would reduce hospital stay, surgical waiting time and indiscriminate use of antibiotics that generate multidrug-resistant microorganisms, thus generating an impact on Public Health and on the quality of care.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Jan 2018
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 30, 2017
CompletedFirst Posted
Study publicly available on registry
September 1, 2017
CompletedStudy Start
First participant enrolled
January 22, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2018
CompletedJanuary 24, 2018
January 1, 2018
8 months
August 30, 2017
January 22, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Bloodstream infection
An infectious process characterized by the presence of some bacteria in the bloodstream. The patient should have one or more positive blood cultures, where the cultured organism is not related to an infection elsewhere, and has signs of infection, such as fever, hypotension or tachycardia.
30 days
Secondary Outcomes (3)
Surgical Site Infection:
30 days
Length of hospital stay
30 days
Re-entry to hospitalization
30 days
Study Arms (3)
Prophylactic antibiotic five days previous to the procedure
ACTIVE COMPARATORProphylactic antibiotic during five days previous to the procedure.
Prophylactic antibiotic three days previous to the procedure
ACTIVE COMPARATORProphylactic antibiotic during three days previous to the procedure.
Only a single dose of Prophylactic antibiotic
EXPERIMENTALOnly a single dose of Prophylactic antibiotic on the day of the procedure
Interventions
Prophylactic antibiotic during five days previous to the procedure.
Prophylactic antibiotic during three days previous to the procedure.
This group will receive a single dose of antibiotic 90 ± 20 minutes prior to the start of the surgical procedure (incision)
Eligibility Criteria
You may qualify if:
- Age ≥ 18 years
- Patients with asymptomatic bacteriuria identified with a urine culture prior to the surgical procedure and with a microorganism that meets the following criteria: 1) gram-negative bacteria in the enterobacterial family and non-fermenting bacilli; 2) Bacteria with resistance profile has a therapeutic option that reaches therapeutic concentration in urine.
- Patients scheduled for urological procedures, such as: transurethral resection of the prostate, open prostatectomy, cystoscopy, extracorporeal lithotripsy and flexible ureterorenoscopy.
- Informed consent
You may not qualify if:
- Patients with chronic renal failure; with immunosuppressive status secondary to glucocorticoid consumption, haematological or solid organ neoplasms undergoing chemotherapy or radiation therapy or neutropenia.
- Patients with active infection or clinical criteria of urinary infection.
- Patients who voluntarily do not want to participate in the study.
- Patients who can not give informed consent under reasonable or vulnerable conditions.
- Patients who present type I allergy to penicillin.
- Patients who have scheduled surgeries combined with a discipline different to urology.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Universidad CES
Medellín, Antioquia, 00000, Colombia
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- INVESTIGATOR, OUTCOMES ASSESSOR
- Masking Details
- A single blinding will be performed. To the database will be categorized the variable "duration of prophylaxis" so that the person in charge of analysing the data, does not know the true allocation of each of the participants. At the end of the tabulation and analysis of the data, the true allocation will be known.
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Ph. D. student in Public Health
Study Record Dates
First Submitted
August 30, 2017
First Posted
September 1, 2017
Study Start
January 22, 2018
Primary Completion
October 1, 2018
Study Completion
November 1, 2018
Last Updated
January 24, 2018
Record last verified: 2018-01